Investigational drugs targeting fibroblast growth factor receptor in the treatment of non-small cell lung cancer. (4th May 2017)

• Record Type: Journal Article
• Authors: Rijavec, Erika; Genova, Carlo; Barletta, Giulia; Biello, Federica; Rossi, Giovanni; Tagliamento, Marco; Dal Bello, Maria Giovanna; Coco, Simona; Vanni, Irene; Boccardo, Simona; Alama, Angela; Grossi, Francesco
• Is Part Of: Expert opinion on investigational drugs. Volume 26:Number 5(2017)
• Page Start: 551
• Page End: 561
• Publication Date: 2017-05-04
• Subjects: FGFR -- NSCLC -- FGFR TKI -- FGF; Drugs -- Design -- Periodicals; Drugs, Investigational -- Bibliography; Drugs, Investigational -- Periodicals; 615.1
• DOI: 10.1080/13543784.2017.1316714
• Languages: English
• ISSNs: 1354-3784

Abstract

ABSTRACT: Introduction : Fibroblast growth factor receptor (FGFR) due to its central role in regulating cell survival, is a promising target for cancer therapeutics. Dysregulation of the FGFR pathway has been observed in several malignancies, including non-small cell lung cancer (NSCLC) particularly in patients with squamous histology. Areas covered : The aim of this article is to review the most relevant findings of clinical trials investigating drugs targeting FGFR pathway: such as FGFR tyrosine kinase inhibitors (TKIs), FGFR monoclonal antibodies and FGF ligand traps in NSCLC patients. Expert opinion : At present, clinical activity of drugs targeting FGFR in NSCLC is disappointing. Further studies are needed in order to better identify patients who might benefit from these drugs and to clarify the mechanisms of resistance to these compounds.